Showing 1 posts of 1 posts found.
Axsome Therapeutics reported on Monday that its Phase 3 study of its experimental depression drug missed its main trial goal. …
MHRA approves first lower-carbon beclometasone inhalers for asthma
Samsung Biologics launches bid to acquire peptide CDMO PolyPeptide
Novogenia breaks ground on personalised healthcare campus
InfectoPharm launches Polish operations with first hospital antibiotic
FibroFind appoints Lee Borthwick as CEO